{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:46:09Z","timestamp":1760060769569,"version":"build-2065373602"},"reference-count":31,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The prognosis for recurrent ovarian cancer is poor, but a small percentage of patients can be cured. The aim of this study was to clarify the criteria for being cured and the characteristics of cured cases. Methods: Ovarian cancer cases at 2 university hospitals and 8 community hospitals were analyzed to identify patients who were considered cured after complete remission (CR) following recurrence. Analyses of the tumors were performed and included BRCA1\/2 mutation analysis. Results: Of the 157 cases of recurrence, 21 (13%) showed no evidence of disease (NED). NED cases had a lower rate of ascites at the initial diagnosis, longer disease-free survival, a higher rate of solitary lesions, and a higher rate of secondary debulking surgery. All CR cases except for one showed no further recurrence when DFS reached 4 years, which was considered a criterion for being cured. The case of relapse occurred after long-term treatment with bevacizumab. Furthermore, 19.4% of the CR cases achieved 4-year DFS, which represents 9.3% of the cases of recurrent ovarian cancer and 2.3% of all cases of ovarian cancer. BRCA mutation analysis of the tumor was possible in 17 of the 30 cases of recurrent ovarian cancer that achieved a 4-year DFS. Pathogenic variants of BRCA were found in 5 of the 11 cases of high-grade serous carcinoma. Conclusions: Approximately 10% of patients with recurrent ovarian cancer achieved a 4-year DFS and were mostly cured. The curing of cases not involving high-grade serous carcinoma (HGSC) was unrelated to the presence of pathogenic BRCA variants.<\/jats:p>","DOI":"10.3390\/cancers17183069","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T16:53:42Z","timestamp":1758300822000},"page":"3069","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cure of Recurrent Ovarian Cancer: A Multicenter Retrospective Study"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1141-5618","authenticated-orcid":false,"given":"Masahiro","family":"Sumitomo","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osakasayama 589-8511, Japan"},{"name":"Department of Obstetrics and Gynecology, Tenri Hospital, Tenri 632-8552, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8712-1806","authenticated-orcid":false,"given":"Yasushi","family":"Kotani","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osakasayama 589-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4278-5849","authenticated-orcid":false,"given":"Kosuke","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osakasayama 589-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Abiko","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-8641, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Genome Biology, Kindai University Faculty of Medicine, Osakasayama 589-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4351-324X","authenticated-orcid":false,"given":"Tomoyuki","family":"Otani","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kindai University Faculty of Medicine, Osakasayama 589-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8139-9292","authenticated-orcid":false,"given":"Akihiko","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayo","family":"Ukita","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shizuoka General Hospital, Shizuoka 420-8527, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Taga","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Japanese Red Cross Otsu Hospital, Otsu 520-0046, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuko","family":"Emoto","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3770-7099","authenticated-orcid":false,"given":"Kentaro","family":"Sekiyama","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Medical Research Institute Kitano Hospital, Osaka 530-8480, Japan"},{"name":"Department of Obstetrics and Gynecology, Kindai University Nara Hospital, Ikoma 630-0293, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minami","family":"Okudate","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kobe City Medical Center General Hospital, Kobe 650-0047, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motonori","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan"},{"name":"Department of Obstetrics and Gynecology, Toyooka Hospital, Toyooka 668-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Yamanishi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Japanese Red Cross Wakayama Medical Center, Wakayama 640-8558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8275-0846","authenticated-orcid":false,"given":"Kazuto","family":"Nishio","sequence":"additional","affiliation":[{"name":"Department of Genome Biology, Kindai University Faculty of Medicine, Osakasayama 589-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Mandai","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4512-7975","authenticated-orcid":false,"given":"Noriomi","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osakasayama 589-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10147-024-02473-8","article-title":"Trends in gynecologic cancer in Japan: Incidence from 1980 to 2019 and mortality from 1981 to 2021","volume":"29","author":"Nakai","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1097\/NCC.0000000000000415","article-title":"What Do Ovarian Cancer Patients Expect from Treatment?: Perspectives from an Online Patient Community","volume":"40","author":"Simacek","year":"2017","journal-title":"Cancer Nurs."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","volume":"119","author":"Friedlander","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ygyno.2022.08.021","article-title":"Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma","volume":"167","author":"Oza","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.21873\/anticanres.11110","article-title":"What Characterizes Long-term Survivors of Recurrent Ovarian Cancer? Case Report and Review of the Literature","volume":"36","author":"Hilal","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_9","first-page":"6523","article-title":"Curative cancer chemotherapy","volume":"45","author":"Frei","year":"1985","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/jjco\/hyi109","article-title":"A new, accurate and conventional five-point method for quantitative evaluation of ascites using plain computed tomography in cancer patients","volume":"35","author":"Oriuchi","year":"2005","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Cline, M.S., Liao, R.G., Parsons, M.T., Paten, B., Alquaddoomi, F., Antoniou, A., Baxter, S., Brody, L., Cook-Deegan, R., and Coffin, A. (2018). BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genet., 14.","DOI":"10.1371\/journal.pgen.1007752"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1007\/s10147-022-02214-9","article-title":"Who are the long-term survivors of recurrent ovarian carcinoma?: A retrospective analysis of a multicenter study","volume":"27","author":"Yoshihara","year":"2022","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3892\/mco.2017.1266","article-title":"Factors favouring long-term survival following recurrence in ovarian cancer","volume":"7","author":"Soyama","year":"2017","journal-title":"Mol. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10147-014-0687-1","article-title":"Clinical features of long-term survivors of recurrent epithelial ovarian cancer","volume":"20","author":"Iwase","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/IGC.0b013e318286665b","article-title":"Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: An Italian multicenter retrospective study","volume":"23","author":"Gadducci","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ygyno.2009.11.008","article-title":"The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: A multicenter retrospective Italian study","volume":"116","author":"Gadducci","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ygyno.2021.12.022","article-title":"Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis","volume":"164","author":"Corrigan","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/IGC.0000000000001294","article-title":"Long-Term Survival After Surgery and Radiotherapy for Recurrent or Persistent Ovarian and Tubal Cancer","volume":"28","author":"Rome","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ygyno.2015.09.011","article-title":"Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer","volume":"139","author":"Eng","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1007\/s10147-022-02169-x","article-title":"The roles and limitations of bevacizumab in the treatment of ovarian cancer","volume":"27","author":"Nakai","year":"2022","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Takamatsu, S., Nakai, H., Yamaguchi, K., Hamanishi, J., Mandai, M., and Matsumura, N. (2023). Time-Dependent Changes in Risk of Progression During Use of Bevacizumab for Ovarian Cancer. JAMA Netw. Open, 6.","DOI":"10.1101\/2023.02.14.23285833"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): A multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/s41416-022-02122-9","article-title":"Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study","volume":"128","author":"Takamatsu","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Takaya, H., Nakai, H., Takamatsu, S., Mandai, M., and Matsumura, N. (2020). Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-59671-3"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1111\/cas.15747","article-title":"Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 Study","volume":"114","author":"Yoshihara","year":"2023","journal-title":"Cancer Sci."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Takamatsu, S., Brown, J.B., Yamaguchi, K., Hamanishi, J., Yamanoi, K., Takaya, H., Kaneyasu, T., Mori, S., Mandai, M., and Matsumura, N. (2022). Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types. JCO Precis Oncol., 6.","DOI":"10.1200\/PO.22.00085"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ygyno.2014.10.009","article-title":"Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States","volume":"136","author":"Fuh","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1200\/JCO.2008.20.8793","article-title":"Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A model for assessing population-related pharmacogenomics","volume":"27","author":"Gandara","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1007\/s10147-022-02212-x","article-title":"Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer","volume":"27","author":"Yoshihama","year":"2022","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Pautier","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/18\/3069\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:46:07Z","timestamp":1760035567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/18\/3069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":31,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["cancers17183069"],"URL":"https:\/\/doi.org\/10.3390\/cancers17183069","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,9,19]]}}}